var data={"title":"Buschke-Ollendorff syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Buschke-Ollendorff syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/contributors\" class=\"contributor contributor_credentials\">Catherine McCuaig, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/contributors\" class=\"contributor contributor_credentials\">Barbara Miedzybrodzki, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/contributors\" class=\"contributor contributor_credentials\">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 20, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H2793311278\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Buschke-Ollendorff syndrome (BOS) (MIM #166700) is a rare, inherited autosomal-dominant disorder with high penetrance and variable expressivity characterized by the presence of sclerotic bone lesions (osteopoikilosis, &quot;spotted bones&quot;) and, rarely, melorheostosis in association with connective tissue nevi (CTN, elastomas and collagenomas) [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Most patients present both CTN and bone lesions, but some have only skin or skeletal lesions. Both skin and skeletal lesions are usually asymptomatic and in most cases discovered incidentally.</p><p class=\"headingAnchor\" id=\"H1665661375\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>First described in 1928 by Buschke and Ollendorff as dermatofibrosis lenticularis disseminata, the disease has been reported under a variety of names, including dermatofibrosis lenticularis disseminata with osteopoikilosis, dermatofibrosis disseminated with osteopoikilosis, dermato-osteopoikilosis, dermato-osteopoikilosis with melorheostosis (a dripping wax appearance along the outer bone), osteopathia condensans disseminata, and connective tissue nevus syndrome.</p><p class=\"headingAnchor\" id=\"H1950809892\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>BOS is a rare condition. The precise incidence and prevalence are unknown, as both the cutaneous and bone lesions are usually asymptomatic and detected incidentally [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/2-4\" class=\"abstract_t\">2-4</a>]. Males and females are equally affected. Both inherited and sporadic forms have been described [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. </p><p class=\"headingAnchor\" id=\"H3945094364\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>BOS is an autosomal dominant disorder with high penetrance and variable expressivity caused by loss-of-function germline mutations in the <em>LEM </em>domain-containing protein 3<em> </em>(<em>LEMD3</em>) gene (also called <em>MAN1</em>) on chromosome 12q14 [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/6\" class=\"abstract_t\">6</a>]. More than 125 pathogenic mutations of the <em>LEMD3</em> gene have been detected, the vast majority of which are point mutations [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/7-9\" class=\"abstract_t\">7-9</a>]. There are two reports that highlight that a localized loss of the RNA recognition motif (RRM) of the <em>LEMD3</em>, and not necessarily the loss of the entire LEMD3 protein, can also cause the characteristic findings of BOS [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/8,9\" class=\"abstract_t\">8,9</a>]. In addition, even patients who possess the same genetic defect will show differences in skin and bone expression. There is a single report of BOS occurring in a family without an <em>LEMD3</em> mutation [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. There is also a case report of a young girl and her mother who had clinical findings compatible with BOS, although no <em>LEMD3</em> mutation could be identified [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/10\" class=\"abstract_t\">10</a>]. Therefore, there are likely other potential genes involved in the pathogenesis of BOS and connective tissue nevi (CTN).</p><p><em>LEMD3</em> encodes an inner nuclear membrane protein that antagonizes the bone morphogenic proteins (BMPs) and transforming growth factor (TGF)-beta signalling pathways through interactions with specific SMAD family proteins. Loss-of-function mutations in <em>LEMD3</em> result in upregulation of the downstream targets in both of these pathways, leading to alteration of fibroblast function and increased bone formation. Fibroblasts in affected patients produce more tropoelastin and elastin via enhanced TGF-beta and BMP signaling, resulting in the characteristic cutaneous phenotype [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/11,12\" class=\"abstract_t\">11,12</a>]. </p><p>The exact pathogenesis of osteopoikilosis (OPK) is unknown; it is thought to be a multifactorial process that may involve [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/13\" class=\"abstract_t\">13</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An inherited abnormal formation of trabeculae along lines of stress</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A focal defect of endochondral ossification</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered osteogenesis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Specific <em>LEMD3</em> mutations </p><p/><p>Melorheostosis is a mixed sclerosing bone dysplasia characterized by abnormalities of endochondral and membranous ossification [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. It is characterized by ectopic bone formation on the periosteal and endosteal surface of the long bones [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/15\" class=\"abstract_t\">15</a>]. The observation that the disorder tends to be segmental and unilateral suggests a defect in the early embryologic stage. Although specific <em>LEMD3</em> mutations have been identified in patients with BOS who present with OPK associated with melorheostosis [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/16\" class=\"abstract_t\">16</a>], no germline <em>LEMD3</em> mutations have been identified in cases of isolated melorheostosis.</p><p class=\"headingAnchor\" id=\"H3055490799\"><span class=\"h1\">PATHOLOGY</span></p><p class=\"headingAnchor\" id=\"H14893924\"><span class=\"h2\">Skin lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since routine hematoxylin and eosin stains cannot differentiate collagen and elastic fiber, special stains are required for the accurate histopathologic diagnosis of connective tissue nevi (CTN). These include hematoxylin phloxine saffron stain, which stains collagen in yellow and elastic fibers in red; Masson's trichrome stain; orcein; Weigert; and Verhoeff-van Gieson [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/8,17-22\" class=\"abstract_t\">8,17-22</a>]. </p><p>CTN typically show a normal or papillomatous epidermis overlying an unaffected papillary dermis. Based upon the predominance of collagen or elastic fibers in the reticular dermis, CTN have been divided into four histopathologic groups: pure collagenoma, pure elastoma, mixed CTN, and a newly described variant termed cellular CTN [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/23\" class=\"abstract_t\">23</a>]. However, the histopathologic findings can be very heterogeneous, with most lesions showing both collagen and elastic fiber abnormalities. &#160;</p><p>Pure collagenoma demonstrates accumulation of dense and coarse collagen fibers in the reticular dermis with either an irregular or regular distribution, sometimes associated with a relative reduction in the number of elastic fibers (<a href=\"image.htm?imageKey=DERM%2F109065\" class=\"graphic graphic_picture graphicRef109065 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/23\" class=\"abstract_t\">23</a>]. Pure elastomas show broad, ramified, interlaced, and sometimes clumped elastic fibers in the reticular dermis, whereas mixed-type CTN show both collagen and elastic fiber abnormalities without a specific pattern (<a href=\"image.htm?imageKey=DERM%2F109067\" class=\"graphic graphic_picture graphicRef109067 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/18\" class=\"abstract_t\">18</a>]. A so-called cellular variant of CTN with an increased number of fibroblasts has also been described [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/23\" class=\"abstract_t\">23</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H2002614655\"><span class=\"h2\">Bone lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone lesions of osteopoikilosis are not routinely biopsied, unless there is doubt about the underlying diagnosis. On histopathologic assessment, sclerotic bone samples demonstrate foci of thickened trabeculae of lamellar bone. These foci vary in thickness but are arranged in a regular pattern, similar to that of normal spongiosus bone. This histology is similar to that of bone islands. Osteoclasts and osteoblasts are present in the sections, although they do not show increased activity [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/24\" class=\"abstract_t\">24</a>].</p><p>Histopathologic features of melorheostosis include variable degrees of cortical bone thickening and fibrotic changes within the bone marrow space. The bone structure is irregular, with mixed areas of lamellar and woven bone. The associated soft tissue masses are composed of a mixture of osteocartilaginous, fibrovascular, and adipose tissue [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H3443014994\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>BOS is characterized by the association of multiple connective tissue nevi (CTN), a clinical picture also called &quot;dermatofibrosis lenticularis disseminata,&quot; with osteopoikilosis (OPK, &quot;spotted bones&quot;). Although most patients manifest both cutaneous and skeletal involvement, some may have only skin or skeletal lesions [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. Both CTN and OPK typically appear before puberty and tend to be progressive over time. There are a few reports of cases with onset during infancy or late adulthood [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/7,25-27\" class=\"abstract_t\">7,25-27</a>]. </p><p class=\"headingAnchor\" id=\"H3054100056\"><span class=\"h2\">Connective tissue nevi</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CTN are dermal hamartomas characterized by abnormal accumulation of components of the extracellular dermal matrix, specifically collagen, elastin, and proteoglycans [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/17\" class=\"abstract_t\">17</a>]. Based upon the predominant component found on histologic examination, CTN can be classified into collagenomas, elastomas, or mucinous nevi. (See <a href=\"#H14893924\" class=\"local\">'Skin lesions'</a> above.)</p><p>Elastomas are the most common type of CTN found in patients with BOS. Collagenomas or CTN with mixed features of elastoma and collagenoma have been reported in approximately one-third of patients [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. &#160;</p><p>CTN may present as disseminated flesh-colored or yellowish papules, 2 to 5 mm in size (dermatofibrosis lenticularis disseminata), or as more localized, grouped nodules or plaques (<a href=\"image.htm?imageKey=DERM%2F107838%7EDERM%2F109069\" class=\"graphic graphic_picture graphicRef107838 graphicRef109069 \">picture 3A-B</a>). The disseminated lesions are symmetrically distributed primarily on the trunk and volar surface of the proximal extremities. Rarely, the neck, scalp, face, and hands can be involved (<a href=\"image.htm?imageKey=DERM%2F109070\" class=\"graphic graphic_picture graphicRef109070 \">picture 4</a>). Localized plaques are usually located on the trunk and limbs in a segmental, zosteriform, or linear pattern. CTN are typically asymptomatic. Pruritus, pain, or functional limitations have been only rarely reported [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/27-30\" class=\"abstract_t\">27-30</a>].</p><p>A new syndromic BOS variant, characterized by late-onset generalized morphea, lichen sclerosus and atrophicus, and osteopoikilosis, has been reported in a patient with an identified new mutation in <em>LEMD3</em> [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/31\" class=\"abstract_t\">31</a>]. </p><p class=\"headingAnchor\" id=\"H3285069024\"><span class=\"h2\">Skeletal lesions</span></p><p class=\"headingAnchor\" id=\"H1142459697\"><span class=\"h3\">Osteopoikilosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>OPK (also called osteopathia condensans disseminata, spotted bones, osteosclerosis disseminata, osteosclerosis familiaris disseminata, and osteosclerosis fragilis generalisata) is a sclerosing bone dysplasia consisting of focal deposits of dense lamellar bone in the spongiosa [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. In BOS, OPK displays incomplete penetrance and variable phenotypic expression and may, therefore, not be detected in all patients or be the sole manifestation of the disease [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/2\" class=\"abstract_t\">2</a>].</p><p>OPK typically affects the small tubular bones of hands and feet, meta-epiphyseal region of long bones, and pelvic bones. The hands are involved in nearly all patients, followed by the feet, pelvis, and long bones [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/32\" class=\"abstract_t\">32</a>]. The ribs, skull, and vertebrae are typically spared. Lesions are symmetric but randomly distributed [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/33\" class=\"abstract_t\">33</a>]. </p><p>OPK is usually asymptomatic and is typically an incidental finding on imaging studies for unrelated conditions. Some patients may report articular pain or, rarely, joint effusions [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/2,3,34-36\" class=\"abstract_t\">2,3,34-36</a>]. However, whether these symptoms are truly related to the underlying osteopoikilotic lesions remains to be established. </p><p>Although OPK can present at any age, it is in most cases detected by late childhood or puberty. Lesions usually persist throughout life. </p><p class=\"headingAnchor\" id=\"H1085809418\"><span class=\"h4\">Radiologic findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On plain radiographs, osteopoikilotic lesions appear as round, oval, or linear hyperdense opacities, ranging in size from 2 to 10 mm (<a href=\"image.htm?imageKey=DERM%2F109072\" class=\"graphic graphic_picture graphicRef109072 \">picture 5</a>). The lesion number in a single bone ranges from a few to hundreds and tends to increase with age. The largest number of lesions is usually detected in the pelvic bones [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/32\" class=\"abstract_t\">32</a>]. In children, lesions may increase or decrease in size over time and in rare instances may even disappear completely [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/3\" class=\"abstract_t\">3</a>]. In adults, osteopoikilotic lesions are usually stable and persist throughout life [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/35\" class=\"abstract_t\">35</a>].</p><p class=\"headingAnchor\" id=\"H3162946715\"><span class=\"h3\">Melorheostosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Melorheostosis is a sclerosing bone dysplasia characterized by a &quot;flowing&quot; hyperostosis of the cortex of tubular bones with a radiologic appearance of dripping candle wax [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. Melorheostosis is an uncommon manifestation of BOS, alone or in association with OPK (mixed sclerosing bone dysplasia) [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. Associated abnormalities of adjacent soft tissues such as muscle atrophy, contractures, and sclerodermatous skin lesions have been reported in some patients [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/6,24,31,37\" class=\"abstract_t\">6,24,31,37</a>]. A review of cases of <em>LEMD3</em>-associated skin and bony lesions reported 28 cases of melorheostosis associated with linear scleroderma. In most cases, the skin lesions were overlying the bone lesions and onset was in childhood [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/31\" class=\"abstract_t\">31</a>].</p><p>Melorheostosis may affect a single bone (monostotic form) or multiple adjacent bones (polyostotic form) and typically has a unilateral or segmental distribution. These lesions are in most cases asymptomatic and found incidentally on imaging studies for unrelated conditions. However, in some patients, melorheostosis may be associated with limb stiffness <span class=\"nowrap\">and/or</span> chronic pain and reduced range of motion [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/14,38\" class=\"abstract_t\">14,38</a>]. </p><p class=\"headingAnchor\" id=\"H907730805\"><span class=\"h2\">Associated conditions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although there is no definite link between BOS and other diseases, multiple associations have been described in the literature, most often in single case reports. They include ossifying fibroma [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/39\" class=\"abstract_t\">39</a>]; bilateral cutaneous syndactyly [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/40\" class=\"abstract_t\">40</a>]; otosclerosis and congenital spine stenosis [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/41\" class=\"abstract_t\">41</a>]; hypertrophic scarring [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/42\" class=\"abstract_t\">42</a>]; and pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/43\" class=\"abstract_t\">43</a>]. </p><p>However, it is unclear if these are true associations or coincidental findings. Syndromic manifestations in the spectrum of the 12q14 microdeletion syndrome that encompasses <em>LEMD3</em>, including short stature and developmental delay, have also been reported in association with BOS [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/44\" class=\"abstract_t\">44</a>]. </p><p class=\"headingAnchor\" id=\"H2648394026\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no specific diagnostic criteria for BOS. The diagnosis is suspected in a patient presenting with multiple cutaneous lesions with histopathologic features of connective tissue nevi (CTN) or in a patient with osteopoikilotic lesions found incidentally on radiologic studies for unrelated conditions. (See <a href=\"#H1085809418\" class=\"local\">'Radiologic findings'</a> above.)</p><p class=\"headingAnchor\" id=\"H2603517028\"><span class=\"h2\">Diagnostic workup</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnostic workup of a patient with suspected BOS may involve a careful personal and family history, physical examination, a skin biopsy, radiologic studies, and genetic testing. &#160; &#160;</p><p class=\"headingAnchor\" id=\"H1382444252\"><span class=\"h3\">History and physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients should be questioned for any personal or family history of skin lesions diagnosed either clinically or histopathologically as CTN as well as of any bone lesions found on radiologic investigations suggestive of osteopoikilosis (OPK). Any prior imaging studies from the patient and from any suspected affected family members should also be reviewed. Because of the highly variable expressivity of the disease, the extent of specific skin and skeletal findings is unpredictable within any affected family. </p><p>Total body skin examination should be performed to identify CTN or other skin lesions. Although CTN are in most cases the initial manifestation of BOS, they may go unnoticed if they are small and in limited number. Musculoskeletal examination is often noncontributory since OPK is usually asymptomatic. (See <a href=\"#H3443014994\" class=\"local\">'Clinical manifestations'</a> above.)</p><p class=\"headingAnchor\" id=\"H3439933085\"><span class=\"h3\">Skin biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A 5 to 6 mm full-thickness punch biopsy that includes lesional and perilesional normal skin for comparison will provide an optimal specimen for histopathologic assessment [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/17\" class=\"abstract_t\">17</a>]. In addition to routine histologic stains, specific elastic and collagen fiber staining is required to determine the CTN type. (See <a href=\"#H3055490799\" class=\"local\">'Pathology'</a> above.)</p><p>Skeletal lesions are not normally biopsied, as the diagnosis of OPK can usually be confirmed by means of radiographic imaging.</p><p class=\"headingAnchor\" id=\"H268975392\"><span class=\"h3\">Radiologic imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who present with multiple CTN warrant radiologic investigation with plain radiographs to detect OPK lesions. These lesions typically appear as multiple rounded, dense opacities randomly and symmetrically distributed. (See <a href=\"#H1085809418\" class=\"local\">'Radiologic findings'</a> above.) </p><p>The extent of imaging studies required in each patient should be determined on a case-by-case basis. Although a whole-body radiographic bone survey would be most informative, many authors recommend a conservative &quot;high-yield&quot; approach to decrease exposure to radiation, which includes plain anteroposterior radiographs of the hands, wrists, feet, ankles, knees, and pelvis [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/17,41\" class=\"abstract_t\">17,41</a>]. Given the benign nature of BOS, even more limited radiographic examinations can be performed in young children [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/45\" class=\"abstract_t\">45</a>]. </p><p>If performed, computed tomography shows numerous areas of hyperdense, well-rounded sclerotic foci [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/3,46\" class=\"abstract_t\">3,46</a>]. Bone scintigraphy is not usually done unless the diagnosis is uncertain and there is a suspicion for bone metastases. (See <a href=\"#H4173501717\" class=\"local\">'Differential diagnosis'</a> below.) </p><p class=\"headingAnchor\" id=\"H2108611748\"><span class=\"h3\">Genetic testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genetic testing is not routinely performed to confirm the diagnosis of BOS in patients with characteristic clinical and radiologic findings. However, if the diagnosis is uncertain, genetic analysis for germline mutations in the <em>LEMD3</em> gene may be helpful to confirm the diagnosis and differentiate BOS from other conditions associated with either CTN or sclerotic bone lesions. New mutations within the <em>LEMD3</em> gene are being described [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/9,10,31,47\" class=\"abstract_t\">9,10,31,47</a>].</p><p class=\"headingAnchor\" id=\"H4173501717\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H1927993110\"><span class=\"h2\">Connective tissue nevi</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Connective tissue nevi (CTN), and in particular collagenomas, can be sporadic or associated with a number of inherited or congenital disorders, including [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/17\" class=\"abstract_t\">17</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Eruptive <span class=\"nowrap\">collagenoma/papular</span> elastorrhexis</strong> &ndash; Eruptive collagenoma is a rare, sporadic condition of unknown etiology characterized by acquired, numerous, discrete, firm, skin-colored papules and nodules on the trunk and upper extremities [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/48,49\" class=\"abstract_t\">48,49</a>]. Eruptive collagenoma usually arises in children and young adults. On histology, lesions show thickened collagen bundles in the dermis along with decreased or degenerated elastic fibers. Indeed, &quot;eruptive papular collageno-elastopathy&quot; has been proposed as a new term to unify the two indistinguishable entities: eruptive collagenoma and papular elastorrhexis [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/50\" class=\"abstract_t\">50</a>]. Fine, dense collagen is also characteristic in both, as well as in nevus anelasticus [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/51\" class=\"abstract_t\">51</a>]. The absence of osteopoikilosis (OPK) on plain radiographs of the hands and pelvic bones, and lack of <em>LEMD3</em> mutation, helps to differentiate eruptive collagenoma from BOS [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/20\" class=\"abstract_t\">20</a>]. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Familial cutaneous collagenoma</strong> &ndash; Familial cutaneous collagenoma is a rare autosomal-dominant disorder characterized by the development during adolescence of multiple asymptomatic cutaneous nodules on the trunk and upper arms with histologic features of CTN [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/52,53\" class=\"abstract_t\">52,53</a>]. There are no associated bone abnormalities. A splice-site mutation in the <em>LEM</em> domain-containing protein 3 (<em>LEMD</em>3) gene has been demonstrated in one kindred with familial cutaneous collagenoma [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/54\" class=\"abstract_t\">54</a>]. This finding suggests that familial cutaneous collagenoma and BOS may be allelic disorders. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tuberous sclerosis complex</strong> &ndash; Tuberous sclerosis complex is an inherited neurocutaneous disorder characterized by pleomorphic features involving many organ systems, including multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney, and skin. Among the characteristic skin lesions, the so-called &quot;shagreen patches&quot; are firm, yellowish-pink nodules or plaques with a dimpled surface similar to the orange peel and histopathologic features of CTN (<a href=\"image.htm?imageKey=DERM%2F107894\" class=\"graphic graphic_picture graphicRef107894 \">picture 6</a>).&nbsp;(See <a href=\"topic.htm?path=tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex: Genetics, clinical features, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Multiple Endocrine neoplasia type 1 (MEN1)</strong> &ndash; MEN1 is an autosomal-dominant disorder characterized by a predisposition to tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells and to nonendocrine tumors including lipomas, facial angiofibromas, collagenomas, and melanomas [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/55\" class=\"abstract_t\">55</a>]. (See <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Proteus syndrome</strong> &ndash; Proteus syndrome is an extremely rare disorder comprising of malformations and overgrowth of multiple tissues. When present, a cerebriform plantar collagenoma (<a href=\"image.htm?imageKey=ONC%2F73826\" class=\"graphic graphic_picture graphicRef73826 \">picture 7</a>) is almost pathognomonic for Proteus syndrome. (See <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome#H462460056\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;, section on 'Proteus and Proteus-like syndromes'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Juvenile elastomas</strong> &ndash; Elastomas are almost exclusively found in BOS. The so-called &quot;juvenile elastomas&quot; without associated OPK are thought to be an incomplete manifestation of the disease [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/22\" class=\"abstract_t\">22</a>]. No reports on <em>LEMD3</em> testing in such patients have been published.</p><p/><p class=\"headingAnchor\" id=\"H3981548649\"><span class=\"h2\">Osteopoikilosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most important differential diagnosis of OPK is osteoblastic bone metastasis. Cancers associated with predominantly osteoblastic bone metastasis include prostate cancer; small cell lung cancer; Hodgkin lymphoma; and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome (see related topics). Skeletal scintigraphy with technetium-99m is the initial and the most widely used method to detect osteoblastic bone metastases, which characteristically produce &quot;hot spots&quot; on bone scans due to increased radioisotope uptake [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/13,46,56\" class=\"abstract_t\">13,46,56</a>]. (See <a href=\"topic.htm?path=epidemiology-clinical-presentation-and-diagnosis-of-adult-patients-with-bone-metastasis\" class=\"medical medical_review\">&quot;Epidemiology, clinical presentation, and diagnosis of adult patients with bone metastasis&quot;</a>.)</p><p>OPK may be confused with other inherited or sporadic sclerosing bone dysplasias [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. Focal osteosclerotic lesions may also occur in adult patients with systemic mastocytosis, but in contrast with OPK, they are predominantly located in the axial skeleton [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/57,58\" class=\"abstract_t\">57,58</a>]. (See <a href=\"topic.htm?path=mastocytosis-cutaneous-and-systemic-epidemiology-pathogenesis-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Mastocytosis (cutaneous and systemic): Epidemiology, pathogenesis, and clinical manifestations&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3863524539\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>BOS is a benign disorder that does not require treatment. A<strong> </strong>correct diagnosis is therefore essential to spare patients unnecessary investigations and interventions. </p><p>However, some patients may desire surgical excision of connective tissue nevi because of cosmetic concerns. Pain relief with analgesics or nonsteroidal anti-inflammatory drugs may be indicated in patients with osteopoikilosis who are symptomatic [<a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/13\" class=\"abstract_t\">13</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H150719894\"><span class=\"h1\">PROGNOSIS AND FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>BOS is a benign condition and generally carries an excellent prognosis. Patients <span class=\"nowrap\">and/or</span> parents should be reassured that they can live an active life and expect a normal lifespan. </p><p>There is no specific follow-up required for most patients with BOS, especially if they are asymptomatic. Baseline documentation of skin and bone lesions when discovered is important in order to prevent any misdiagnoses in the future. </p><p class=\"headingAnchor\" id=\"H1607933396\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Buschke-Ollendorff syndrome (BOS) is a rare, inherited autosomal-dominant disorder with high penetrance and variable expressivity caused by loss-of-function germline mutations in the <em>LEM</em> domain-containing protein 3 (<em>LEMD3</em>) gene and characterized by the presence of sclerotic bone lesions (osteopoikilosis [OPK]) in association with connective tissue nevi (CTN). (See <a href=\"#H2793311278\" class=\"local\">'Introduction'</a> above and <a href=\"#H3945094364\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CTN present as disseminated flesh-colored or yellowish papules or as more localized, grouped nodules or plaques (<a href=\"image.htm?imageKey=DERM%2F107838\" class=\"graphic graphic_picture graphicRef107838 \">picture 3A</a>). OPK is a sclerosing bone dysplasia that typically affects the small tubular bones of hands and feet, epiphyseal region of long bones, and pelvic bones. (See <a href=\"#H3443014994\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of BOS is based upon the finding of multiple cutaneous lesions with histopathologic features of CTN associated with OPK detected on plain radiographs. Genetic analysis for germline mutations in the <em>LEMD3</em> gene can confirm the diagnosis in uncertain cases. (See <a href=\"#H2648394026\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>BOS is a benign disorder that does not require treatment. Surgical excision of connective tissue may be performed in some patients for cosmetic reasons. Pain relief with analgesics or nonsteroidal anti-inflammatory drugs may be indicated in patients with OPK who are symptomatic. (See <a href=\"#H3863524539\" class=\"local\">'Management'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">www.omim.org/entry/166700 (Accessed on November 07, 2015).</li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/2\" class=\"nounderline abstract_t\">Pope V, Dupuis L, Kannu P, et al. Buschke-Ollendorff syndrome: a novel case series and systematic review. Br J Dermatol 2016; 174:723.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/3\" class=\"nounderline abstract_t\">Korkmaz MF, Elli M, &Ouml;zkan MB, et al. Osteopoikilosis: report of a familial case and review of the literature. Rheumatol Int 2015; 35:921.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/4\" class=\"nounderline abstract_t\">Borman P, Ozoran K, Aydo&#287; S, Co&#351;kun S. Osteopoikilosis: report of a clinical case and review of the literature. Joint Bone Spine 2002; 69:230.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/5\" class=\"nounderline abstract_t\">Yadegari M, Whyte MP, Mumm S, et al. Buschke-Ollendorff syndrome: absence of LEMD3 mutation in an affected family. Arch Dermatol 2010; 146:63.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/6\" class=\"nounderline abstract_t\">Hellemans J, Preobrazhenska O, Willaert A, et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet 2004; 36:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/7\" class=\"nounderline abstract_t\">Kratzsch J, Mitter D, Ziemer M, et al. Identification of a Novel Point Mutation in the LEMD3 Gene in an Infant With Buschke-Ollendorff Syndrome. JAMA Dermatol 2016; 152:844.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/8\" class=\"nounderline abstract_t\">Zhang Y, Castori M, Ferranti G, et al. Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis. Clin Genet 2009; 75:556.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/9\" class=\"nounderline abstract_t\">Takashima S, Fujita Y, Suzuki S, et al. RNA recognition motif of LEMD3 as a key player in the pathogenesis of Buschke-Ollendorff syndrome. J Dermatol Sci 2016; 81:205.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/10\" class=\"nounderline abstract_t\">Condorelli A, Musso N, Scuderi L, et al. Juvenile elastoma without germline mutations in LEMD3 gene: A case of Buschke-Ollendorff syndrome? Pediatr Dermatol 2017; 34:e345.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/11\" class=\"nounderline abstract_t\">Giro MG, Duvic M, Smith LT, et al. Buschke-Ollendorff syndrome associated with elevated elastin production by affected skin fibroblasts in culture. J Invest Dermatol 1992; 99:129.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/12\" class=\"nounderline abstract_t\">Uitto J, Santa Cruz DJ, Starcher BC, et al. Biochemical and ultrastructural demonstration of elastin accumulation in the skin lesions of the Buschke-Ollendorff syndrome. J Invest Dermatol 1981; 76:284.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/13\" class=\"nounderline abstract_t\">Woyciechowsky TG, Monticielo MR, Keiserman B, Monticielo OA. Osteopoikilosis: what does the rheumatologist must know about it? Clin Rheumatol 2012; 31:745.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/14\" class=\"nounderline abstract_t\">Boulet C, Madani H, Lenchik L, et al. Sclerosing bone dysplasias: genetic, clinical and radiology update of hereditary and non-hereditary disorders. Br J Radiol 2016; 89:20150349.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/15\" class=\"nounderline abstract_t\">Baasanjav S, Jamsheer A, Kolanczyk M, et al. Osteopoikilosis and multiple exostoses caused by novel mutations in LEMD3 and EXT1 genes respectively--coincidence within one family. BMC Med Genet 2010; 11:110.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/16\" class=\"nounderline abstract_t\">Gutierrez D, Cooper KD, Mitchell AL, Cohn HI. Novel Somatic Mutation in LEMD3 Splice Site Results in Buschke-Ollendorff Syndrome with Polyostotic Melorheostosis and Osteopoikilosis. Pediatr Dermatol 2015; 32:e219.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/17\" class=\"nounderline abstract_t\">McCuaig CC, Vera C, Kokta V, et al. Connective tissue nevi in children: institutional experience and review. J Am Acad Dermatol 2012; 67:890.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/18\" class=\"nounderline abstract_t\">Socrier Y, Wann AR, Sigal ML, et al. [Buschke-Ollendorff syndrome]. Ann Dermatol Venereol 2014; 141:164.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/19\" class=\"nounderline abstract_t\">Surrenti T, Callea F, De Horatio LT, et al. Buschke-Ollendorff syndrome: sparing unnecessary investigations. Cutis 2014; 94:97.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/20\" class=\"nounderline abstract_t\">Ca&ntilde;ueto J, Rom&aacute;n C, Santos-Briz &Aacute;, et al. Papular elastorrhexis and Buschke-Ollendorff syndrome are different entities. J Am Acad Dermatol 2011; 65:e7.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/21\" class=\"nounderline abstract_t\">Danielsen L, Midtgaard K, Christensen HE. Osteopoikilosis associated with dermatofibrosis lenticularis disseminata. Arch Dermatol 1969; 100:465.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/22\" class=\"nounderline abstract_t\">Foo CC, Kumarasinghe SP. Juvenile elastoma: a forme fruste of the Buschke-Ollendorff syndrome? Australas J Dermatol 2005; 46:250.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/23\" class=\"nounderline abstract_t\">Saussine A, Marrou K, Delano&eacute; P, et al. Connective tissue nevi: an entity revisited. J Am Acad Dermatol 2012; 67:233.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/24\" class=\"nounderline abstract_t\">Hellemans J, Debeer P, Wright M, et al. Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis. Hum Mutat 2006; 27:290.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/25\" class=\"nounderline abstract_t\">Schena D, Germi L, Zamperetti MR, et al. Buschke-Ollendorff syndrome. Int J Dermatol 2008; 47:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/26\" class=\"nounderline abstract_t\">Woodrow SL, Pope FM, Handfield-Jones SE. The Buschke-Ollendorff syndrome presenting as familial elastic tissue naevi. Br J Dermatol 2001; 144:890.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/27\" class=\"nounderline abstract_t\">Trattner A, David M, Rothem A, et al. Buschke-Ollendorff syndrome of the scalp: histologic and ultrastructural findings. J Am Acad Dermatol 1991; 24:822.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/28\" class=\"nounderline abstract_t\">Schaffenburg WC, Fernelius C, Arora NS. Buschke-Ollendorff syndrome presenting as a painful nodule. JAAD Case Rep 2015; 1:77.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/29\" class=\"nounderline abstract_t\">Kobus RJ, Lubbers LM, Coleman CR. Connective tissue nevus and osteopoikilosis in the hand: the Buschke-Ollendorff syndrome. J Hand Surg Am 1989; 14:535.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/30\" class=\"nounderline abstract_t\">Reinhardt LA, Rountree CB, Wilkin JK. Buschke-ollendorff syndrome. Cutis 1983; 31:94.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/31\" class=\"nounderline abstract_t\">Korman B, Wei J, Laumann A, et al. Mutation in LEMD3 (Man1) Associated with Osteopoikilosis and Late-Onset Generalized Morphea: A New Buschke-Ollendorf Syndrome Variant. Case Rep Dermatol Med 2016; 2016:2483041.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/32\" class=\"nounderline abstract_t\">Benli IT, Akalin S, Boysan E, et al. Epidemiological, clinical and radiological aspects of osteopoikilosis. J Bone Joint Surg Br 1992; 74:504.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/33\" class=\"nounderline abstract_t\">Chigira M, Kato K, Mashio K, Shinozaki T. Symmetry of bone lesions in osteopoikilosis. Report of 4 cases. Acta Orthop Scand 1991; 62:495.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/34\" class=\"nounderline abstract_t\">Kotulska A, Kucharz EJ. Osteopoikilosis and Buschke-Ollendorff syndrome. Case Rep Clin Pract Rev 2002; 3:290.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/35\" class=\"nounderline abstract_t\">Negi RS, Manchanda KL, Sanga S, et al. Osteopoikilosis - Spotted bone disease. Med J Armed Forces India 2013; 69:196.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/36\" class=\"nounderline abstract_t\">Hasan SA, Siddiq AB, Moula A, et al. Osteopoikilosis. Mymensingh Med J 2010; 19:290.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/37\" class=\"nounderline abstract_t\">Debeer P, Pykels E, Lammens J, et al. Melorheostosis in a family with autosomal dominant osteopoikilosis: report of a third family. Am J Med Genet A 2003; 119A:188.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/38\" class=\"nounderline abstract_t\">Greenspan A, Azouz EM. Bone dysplasia series. Melorheostosis: review and update. Can Assoc Radiol J 1999; 50:324.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/39\" class=\"nounderline abstract_t\">Dawson AL, Schulman JM, Jordan RC, North JP. Ossifying fibroma in Buschke-Ollendorff syndrome. J Cutan Pathol 2014; 41:740.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/40\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Faith E, Kress D, Piliang M, et al. Buschke-Ollendorff syndrome and bilateral cutaneous syndactyly. Pediatr Dermatol 2012; 29:661.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/41\" class=\"nounderline abstract_t\">Schnur RE, Grace K, Herzberg A. Buschke-Ollendorff syndrome, otosclerosis, and congenital spinal stenosis. Pediatr Dermatol 1994; 11:31.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/42\" class=\"nounderline abstract_t\">Korekawa A, Nakano H, Toyomaki Y, et al. Buschke-Ollendorff syndrome associated with hypertrophic scar formation: a possible role for LEMD3 mutation. Br J Dermatol 2012; 166:900.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/43\" class=\"nounderline abstract_t\">Gracia-Caza&ntilde;a T, Frias M, Rosell&oacute; R, et al. PASH syndrome associated with osteopoikilosis. Int J Dermatol 2015; 54:e369.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/44\" class=\"nounderline abstract_t\">Buysse K, Reardon W, Mehta L, et al. The 12q14 microdeletion syndrome: additional patients and further evidence that HMGA2 is an important genetic determinant for human height. Eur J Med Genet 2009; 52:101.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/45\" class=\"nounderline abstract_t\">Verbov J. Buschke--Ollendorff syndrome (disseminated dermatofibrosis with osteopoikilosis). Br J Dermatol 1977; 96:87.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/46\" class=\"nounderline abstract_t\">Tuncel M, Caner B. Osteopoikilosis: a major diagnostic problem solved by bone scintigraphy. Rev Esp Med Nucl Imagen Mol 2012; 31:93.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/47\" class=\"nounderline abstract_t\">Lafargue O, Fraitag S, Boccara O, et al. [Extensive connective tissue nevus in children]. Ann Dermatol Venereol 2017; 144:700.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/48\" class=\"nounderline abstract_t\">Sharma R, Verma P, Singal A, Sharma S. Eruptive collagenoma. Indian J Dermatol Venereol Leprol 2013; 79:256.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/49\" class=\"nounderline abstract_t\">McClung AA, Blumberg MA, Huttenbach Y, et al. Development of collagenomas during pregnancy. J Am Acad Dermatol 2005; 53:S150.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/50\" class=\"nounderline abstract_t\">Kuwatsuka S, Kuwatsuka Y, Tomimura S, Utani A. Proposal of the new name &quot;eruptive papular collageno-elastopathy&quot; to unify the two indistinguishable entities, eruptive collagenoma and papular elastorrhexis. J Dermatol 2015; 42:440.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/51\" class=\"nounderline abstract_t\">Lee SH, Sung NH. The Importance of Collagen Tissue in Papular Elastorrhexis, Eruptive Collagenoma, and Nevus Anelasticus. Ann Dermatol 2016; 28:210.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/52\" class=\"nounderline abstract_t\">Uitto J, Santa-Cruz DJ, Eisen AZ. Familial cutaneous collagenoma: genetic studies on a family. Br J Dermatol 1979; 101:185.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/53\" class=\"nounderline abstract_t\">Park MY, Choi YJ, Lee JY, et al. A case of familial cutaneous collagenoma. Ann Dermatol 2011; 23 Suppl 1:S119.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/54\" class=\"nounderline abstract_t\">Hershkovitz D, Amitai B, Sprecher E. Familial cutaneous collagenomas resulting from a novel mutation in LEMD3. Br J Dermatol 2007; 156:375.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/55\" class=\"nounderline abstract_t\">Vidal A, Iglesias MJ, Fern&aacute;ndez B, et al. Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1. J Eur Acad Dermatol Venereol 2008; 22:835.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/56\" class=\"nounderline abstract_t\">Ozdemirel AE, Cakit BD, Erdem HR, Koc B. A rare benign disorder mimicking metastasis on radiographic examination: a case report of osteopoikilosis. Rheumatol Int 2011; 31:1113.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/57\" class=\"nounderline abstract_t\">Rossini M, Zanotti R, Viapiana O, et al. Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am 2014; 34:383.</a></li><li><a href=\"https://www.uptodate.com/contents/buschke-ollendorff-syndrome/abstract/58\" class=\"nounderline abstract_t\">Alpay Kan&#305;tez N, Erer B, Do&#287;an &Ouml;, et al. Osteoporosis and osteopathy markers in patients with mastocytosis. Turk J Haematol 2015; 32:43.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15515 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1607933396\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H2793311278\" id=\"outline-link-H2793311278\">INTRODUCTION</a></li><li><a href=\"#H1665661375\" id=\"outline-link-H1665661375\">TERMINOLOGY</a></li><li><a href=\"#H1950809892\" id=\"outline-link-H1950809892\">EPIDEMIOLOGY</a></li><li><a href=\"#H3945094364\" id=\"outline-link-H3945094364\">PATHOGENESIS</a></li><li><a href=\"#H3055490799\" id=\"outline-link-H3055490799\">PATHOLOGY</a><ul><li><a href=\"#H14893924\" id=\"outline-link-H14893924\">Skin lesions</a></li><li><a href=\"#H2002614655\" id=\"outline-link-H2002614655\">Bone lesions</a></li></ul></li><li><a href=\"#H3443014994\" id=\"outline-link-H3443014994\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H3054100056\" id=\"outline-link-H3054100056\">Connective tissue nevi</a></li><li><a href=\"#H3285069024\" id=\"outline-link-H3285069024\">Skeletal lesions</a><ul><li><a href=\"#H1142459697\" id=\"outline-link-H1142459697\">- Osteopoikilosis</a><ul><li><a href=\"#H1085809418\" id=\"outline-link-H1085809418\">Radiologic findings</a></li></ul></li><li><a href=\"#H3162946715\" id=\"outline-link-H3162946715\">- Melorheostosis</a></li></ul></li><li><a href=\"#H907730805\" id=\"outline-link-H907730805\">Associated conditions</a></li></ul></li><li><a href=\"#H2648394026\" id=\"outline-link-H2648394026\">DIAGNOSIS</a><ul><li><a href=\"#H2603517028\" id=\"outline-link-H2603517028\">Diagnostic workup</a><ul><li><a href=\"#H1382444252\" id=\"outline-link-H1382444252\">- History and physical examination</a></li><li><a href=\"#H3439933085\" id=\"outline-link-H3439933085\">- Skin biopsy</a></li><li><a href=\"#H268975392\" id=\"outline-link-H268975392\">- Radiologic imaging</a></li><li><a href=\"#H2108611748\" id=\"outline-link-H2108611748\">- Genetic testing</a></li></ul></li></ul></li><li><a href=\"#H4173501717\" id=\"outline-link-H4173501717\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H1927993110\" id=\"outline-link-H1927993110\">Connective tissue nevi</a></li><li><a href=\"#H3981548649\" id=\"outline-link-H3981548649\">Osteopoikilosis</a></li></ul></li><li><a href=\"#H3863524539\" id=\"outline-link-H3863524539\">MANAGEMENT</a></li><li><a href=\"#H150719894\" id=\"outline-link-H150719894\">PROGNOSIS AND FOLLOW-UP</a></li><li><a href=\"#H1607933396\" id=\"outline-link-H1607933396\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15515|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/109065\" class=\"graphic graphic_picture\">- Collagenoma histology</a></li><li><a href=\"image.htm?imageKey=DERM/109067\" class=\"graphic graphic_picture\">- Elastoma histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/107838\" class=\"graphic graphic_picture\">- Connective tissue nevus 1</a></li><li><a href=\"image.htm?imageKey=DERM/109069\" class=\"graphic graphic_picture\">- Connective tissue nevus buttock</a></li><li><a href=\"image.htm?imageKey=DERM/109070\" class=\"graphic graphic_picture\">- Connective tissue nevus retroauricular</a></li><li><a href=\"image.htm?imageKey=DERM/109072\" class=\"graphic graphic_picture\">- Buschke-Ollendorff syndrome bone</a></li><li><a href=\"image.htm?imageKey=DERM/107894\" class=\"graphic graphic_picture\">- Shagreen patch 2</a></li><li><a href=\"image.htm?imageKey=ONC/73826\" class=\"graphic graphic_picture\">- Cerebriform connective tissue nevus plantar foot</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-presentation-and-diagnosis-of-adult-patients-with-bone-metastasis\" class=\"medical medical_review\">Epidemiology, clinical presentation, and diagnosis of adult patients with bone metastasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mastocytosis-cutaneous-and-systemic-epidemiology-pathogenesis-and-clinical-manifestations\" class=\"medical medical_review\">Mastocytosis (cutaneous and systemic): Epidemiology, pathogenesis, and clinical manifestations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">PTEN hamartoma tumor syndrome, including Cowden syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">Tuberous sclerosis complex: Genetics, clinical features, and diagnosis</a></li></ul></div></div>","javascript":null}